ABCAM Plc Result of AGM and Directorate Change (5110W)
November 15 2017 - 02:01AM
UK Regulatory
TIDMABC
RNS Number : 5110W
ABCAM Plc
15 November 2017
For immediate release
15 November 2017
ABCAM PLC
("Abcam" or the "Company")
Result of AGM and Directorate Change
Abcam, a global leader in the supply of life science research
tools, is pleased to announce that all resolutions put to its
Annual General Meeting (the "AGM") held yesterday were duly
passed.
On 11 October 2017, the Company announced that Murray Hennessey
would relinquish his Non-Executive Chairman position and step down
from the Board following the AGM. Accordingly, at today's meeting
the Chairman proposed a motion to withdraw Resolution 6 (To
re-elect Murray Hennessy as a Director). The motion was agreed and
Resolution 6 was withdrawn and not put to the vote.
Following the AGM, Murray Hennessey stepped down as Chairman and
as a Director of the Company and has been replaced as Interim
Chairman by Louise Patten, an existing Non-Executive Director of
the Company. Louise, who does not wish to be considered for the
role, is leading the process to identify a new Chairman and has
agreed to assume the role of Interim Chairman until such time that
a permanent Chairman is appointed.
The Board thanks Murray for his contribution to the Company over
the last six years and wish him well in the future.
For further information, please contact:
Abcam
+ 44 (0) 1223 696 000
Suzanne Smith, Chief Legal Officer and Company Secretary
J.P.Morgan Cazenove - Nominated Advisor & Corporate
Broker
+ 44 (0) 20 7742 4000
James Mitford / Candelle Chong
FTI Consulting
+ 44 (0) 20 3727 1000
Ben Atwell / Brett Pollard / Natalie Garland-Collins
Notes for editors:
About Abcam plc
As an innovator in reagents and tools, Abcam's purpose is to
serve life science researchers globally to achieve their mission,
faster. Providing the research and clinical communities with tools
and scientific support, the Company offers highly validated
biological binders and assays to address important targets in
critical biological pathways.
Already a pioneer in data sharing and ecommerce in the life
sciences, Abcam's ambition is to be the most influential company in
life sciences by helping advance global understanding of biology
and causes of disease, which, in turn, will drive new treatments
and improved health. Two-thirds of the world's 750,000 life science
researchers use Abcam's affinity binders, reagents, biomarkers and
assays and the Company's products are mentioned in over 20,000 of
the 56,000 peer-reviewed papers published each year in the life
sciences.
By actively listening to and collaborating with researchers, the
Company continuously advances its portfolio to address their needs.
A transparent programme of customer reviews and datasheets,
combined with an industry-leading validation initiative, gives
researchers increased confidence in their results.
Abcam's twelve locations are in the world's leading life science
research hubs, enabling local services and multi-language support.
Founded in 1998 and headquartered in Cambridge, UK, the Company
sells to more than 130 countries. Abcam was admitted to AIM in 2005
(AIM: ABC).
To find out more, please visit www.abcam.com and
www.abcamplc.com
Forward looking statements
This announcement, including any information included or
incorporated by reference in this announcement, may contain
forward-looking statements (including words such as "believe",
"expect", "estimate", "intend", "anticipate" and words of similar
meaning) which are based upon current expectations and assumptions
regarding anticipated developments and other factors affecting the
Abcam Group. All statements other than statements of historical
facts may be forward-looking statements and should not be treated
as guarantees of future performance. These forward-looking
statements involve risks and uncertainties, many of which are
beyond the control of the Abcam Group, and there are important
factors that could cause actual results to differ materially from
those expressed or implied by these forward-looking statements.
These forward-looking statements speak only as at the date of this
announcement and accordingly undue reliance should not be placed on
such statements. The Abcam Group does not assume any obligation to,
and does not intend to, revise or update these forward-looking
statements, except as required pursuant to applicable law.
This information is provided by RNS
The company news service from the London Stock Exchange
END
RAGFZLLFDFFEFBF
(END) Dow Jones Newswires
November 15, 2017 02:01 ET (07:01 GMT)
Abcam (LSE:ABC)
Historical Stock Chart
From Feb 2024 to Mar 2024
Abcam (LSE:ABC)
Historical Stock Chart
From Mar 2023 to Mar 2024